The IPO, the tübingen-based Biotech has under curevac take announced already longer, now the project is gradually concrete.With the IPO on the American Nasdaq stock exchange in the vaccine is likely to collect specialist up to $ 245 million.Simultaneously with the IPO, curevac but once again money from the long-term major shareholder Dietmar Hopp.
Susanne Preuß
business correspondent in Stuttgart, Germany.
F. A. Z. Twitter
With this Information, curevac is not, however, active in the Public – it is hiding in almost confusing Abundance of documents, by the securities and exchange Commission in connection with demCurevac stock exchange be published. There it says that Dietmar Hopp had agreed to invest 100 million euros in a private placement simultaneously with the IPO, in which he takes the shares at the price of the first stock market listing.
The shares are then traded later demTickersymbolCVAC, will be offered according to curevac, Mitteilungin an expected price range of 14 to 16 dollars.By public subscription offer will be offered 13.333.333 ordinary shares,it is called beiCurevac.
in addition, it is planned to grant the underwriters a 30-day Option for an additional two million shares. When the IPO is planned exactly, still remains unclear. Between the official announcement and the first note, about four weeks are usually.
number of investors
curevac may be expected for the IPO, with particular attention, because the Start-up of Tübingen as one of the most important companies in the race for a vaccine against the Coronavirus Sars-Cov is 2.This attention was not granted to the competitors biontech.
The Mainz-based company was planning in the previous autumn, the Gang at the Nasdaq with shares in a price range of 18 to 20 dollars, ultimately had to take but settle for a placement price of 15 dollars. Now hatBiontechschon courses reached about 100 dollars and is currently trading at $ 77.
